Chardan Capital Initiates Coverage On Monopar Therapeutics with Buy Rating, Announces Price Target of $60
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Chardan Capital analyst Keay Nakae initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and announces Price Target of $60.
Chardan Capital analyst Keay Nakae initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and announces Price Target of $60.